Skip to main content

Remote Job Finders (RJF)

Drugmakers cherry pick launch regions as MFN creates ‘policy environment like an earthquake’

With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according to a new report from Numerof & Associates.

From process to intelligence: How AI is reshaping people strategy in life sciences

Applying artificial intelligence and automation tactics has played a large role in talent strategy conversations in the past few years. While many organizations initially focused on experimenting with tools and driving adoption to create efficiencies, leading employers are now asking deeper questions.

Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease

September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.

Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’

After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile cardiovascular flops to six over nine weeks.

Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic

Moonwalk Biosciences plans to shepherd its lead obesity asset into first-in-human trials in late 2027. In preclinical studies, MW101 has demonstrated weight loss and fat reduction while maintaining muscle mass.
Scroll to top